IMMP logo

Immutep Limited (IMMP) Company Overview

Profile

Full Name:

Immutep Limited

Sector:

Healthcare

Industry:

Biotechnology

Country:

Australia

IPO:

April 19, 2012

Indexes:

Not included

Description:

Immutep Limited is a biotechnology company focused on developing immunotherapy treatments for cancer and autoimmune diseases. They specialize in enhancing the immune system's response to fight diseases, using innovative therapies that target specific proteins to improve patient outcomes.

Events Calendar

Earnings

Next earnings date:

Feb 27, 2025

Recent quarterly earnings:

Feb 27, 2024

Recent annual earnings:

Aug 31, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 7, 2019

Analyst ratings

Recent major analysts updates

Nov 15, 24 Baird
Outperform
Jun 27, 24 Baird
Outperform
May 17, 24 Capital One
Overweight
Aug 28, 23 Baird
Outperform
Aug 3, 23 Baird
Outperform
Aug 2, 23 Baird
Outperform
May 18, 23 Maxim Group
Buy
Aug 3, 21 Ladenburg Thalmann
Buy
May 29, 18 Maxim Group
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Immutep Quarterly Activities Report Q2 FY25
Immutep Quarterly Activities Report Q2 FY25
Immutep Quarterly Activities Report Q2 FY25
IMMP
globenewswire.comJanuary 31, 2025

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approval Mature data from INSIGHT-003 in 1L NSCLC demonstrates an excellent 32.9-month median overall survival (OS) and 81.0% 24-month OS rate, significantly outperforming historical controls Promising new results in first line head & neck cancer with PD-L1 CPS

Immutep Limited: Continuing To Make The Case For Eftilagimod
Immutep Limited: Continuing To Make The Case For Eftilagimod
Immutep Limited: Continuing To Make The Case For Eftilagimod
IMMP
seekingalpha.comJanuary 28, 2025

Immutep Limited remains a “Buy” due to promising pipeline updates and strong financials, despite inherent high-risk/high-reward dynamics. Key trials for eftilagimod show encouraging results, particularly in non-small cell lung cancer and soft tissue sarcoma, enhancing the drug's potential. Financially, IMMP has a cash runway at least to 2026, supporting ongoing and future clinical trials without immediate funding concerns.

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
IMMP
globenewswire.comDecember 17, 2024

SYDNEY, AUSTRALIA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces favourable initial safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761. Through the first three of five single ascending dose cohorts in healthy participants, there have been no treatment related adverse events.

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
IMMP
globenewswire.comDecember 12, 2024

SYDNEY, AUSTRALIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive clinical results from Cohort B of the TACTI-003 (KEYNOTE-C34) Phase IIb trial. This study evaluates eftilagimod alpha (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in first line recurrent/metastatic head and neck squamous cell carcinoma (1L HNSCC) patients with negative PD-L1 expression.

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients
Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients
Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients
IMMP
seekingalpha.comNovember 15, 2024

Positive results from phase 1 INSIGHT-003 study, using eftilagimod alpha in combination with KEYTRUDA and chemotherapy in treating first-line metastatic non-squamous NSCLC patients. Additional data from the phase 1 INSIGHT-003 study is expected in 2025, with plans to initiate a phase 3 TACTI-004 study targeting the same patient population. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031.

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
IMMP
globenewswire.comNovember 14, 2024

Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 months, with median Progression Free Survival reaching 12.7 months, and a 24-month Overall Survival rate of 81.0% Data from all evaluable patients to date (N=40) demonstrates significant improvement of Overall Response Rate compared to historical controls Safety continues to be favourable with no new safety signals INSIGHT-003, which is nearing completion of enrolment, evaluates efti with the most widely used immunotherapy-chemo combination today in a similar population to upcoming TACTI-004 Phase III trial  SYDNEY, AUSTRALIA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive data from the investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alpha (efti) in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer (1L NSCLC) patients. Prof. Dr. Salah-Eddin Al-Batran of the Frankfurt Institute of Clinical Cancer Research (IKF) and project lead stated, “The strength of these mature survival results coupled with a favourable safety profile in first-line treatment of patients with non-squamous NSCLC, the vast majority of whom have negative or low PD-L1 expression, is very encouraging.

Immutep Quarterly Activities Report Q1 FY25
Immutep Quarterly Activities Report Q1 FY25
Immutep Quarterly Activities Report Q1 FY25
IMMP
globenewswire.comOctober 29, 2024

SYDNEY, AUSTRALIA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on its activities for the quarter ended 30 September 2024 (Q1 FY25).

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
IMMP
globenewswire.comOctober 10, 2024

Media Release SYDNEY, AUSTRALIA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces Marc Voigt, CEO of Immutep, will participate in a fireside chat at the Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 9:30 am ET. The fireside chat will be live on M-Vest.

Immutep: Navigating The Bumps In The Road
Immutep: Navigating The Bumps In The Road
Immutep: Navigating The Bumps In The Road
IMMP
seekingalpha.comOctober 7, 2024

Immutep Limited (IMMP) has shown underwhelming results in their TACTI-003 trial, raising questions about the efficacy of their lead drug, eftilagimod. Despite the disappointing data, IMMP has a strong cash position, giving them a 3-4 year runway to continue their development efforts. The company remains a speculative investment with potential, especially with upcoming results from the AIPAC-003 breast cancer study expected in 2025.

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
IMMP
globenewswire.comSeptember 16, 2024

SYDNEY, AUSTRALIA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive efficacy and safety results from the TACTI-003 Phase IIb trial evaluating eftilagimod alpha (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients (1L HNSCC).

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Immutep Limited?
  • Does Immutep Limited pay dividends?
  • What sector is Immutep Limited in?
  • What industry is Immutep Limited in?
  • What country is Immutep Limited based in?
  • When did Immutep Limited go public?
  • Is Immutep Limited in the S&P 500?
  • Is Immutep Limited in the NASDAQ 100?
  • Is Immutep Limited in the Dow Jones?
  • When was Immutep Limited's last earnings report?
  • When does Immutep Limited report earnings?

What is the ticker symbol for Immutep Limited?

The ticker symbol for Immutep Limited is NASDAQ:IMMP

Does Immutep Limited pay dividends?

No, Immutep Limited does not pay dividends

What sector is Immutep Limited in?

Immutep Limited is in the Healthcare sector

What industry is Immutep Limited in?

Immutep Limited is in the Biotechnology industry

What country is Immutep Limited based in?

Immutep Limited is headquartered in Australia

When did Immutep Limited go public?

Immutep Limited's initial public offering (IPO) was on April 19, 2012

Is Immutep Limited in the S&P 500?

No, Immutep Limited is not included in the S&P 500 index

Is Immutep Limited in the NASDAQ 100?

No, Immutep Limited is not included in the NASDAQ 100 index

Is Immutep Limited in the Dow Jones?

No, Immutep Limited is not included in the Dow Jones index

When was Immutep Limited's last earnings report?

Immutep Limited's most recent earnings report was on Feb 27, 2024

When does Immutep Limited report earnings?

The next expected earnings date for Immutep Limited is Feb 27, 2025